drugset / Trial / NCT07306949
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acoramidis | Unknown | 800 mg | Oral |
Indications
No indication recorded.